PROCOMP
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PROCOMP (PROCOMP).
The combination of acetaminophen, caffeine, and isometheptene exerts its effects through multiple mechanisms: acetaminophen inhibits cyclooxygenase (COX) enzymes in the CNS, reducing prostaglandin synthesis and pain; caffeine is a non-selective adenosine receptor antagonist that enhances pain relief; isometheptene is a sympathomimetic amine that constricts dilated cerebral blood vessels.
| Metabolism | Acetaminophen: primarily metabolized by glucuronidation and sulfation in the liver with minor CYP2E1-mediated oxidation to a hepatotoxic metabolite (NAPQI). Caffeine: hepatic metabolism via CYP1A2 (demethylation to paraxanthine). Isometheptene: not well characterized; likely hepatic metabolism. |
| Excretion | Renal: 60% as unchanged drug; biliary/fecal: 30% as metabolites; total recovery ~90% in urine and feces within 72 hours. |
| Half-life | Terminal elimination half-life: 12-18 hours (mean 15 hours). Steady-state reached within 3-5 days; clinical effect correlates with trough concentrations. |
| Protein binding | 98% bound primarily to albumin, with minor binding to alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.3-0.5 L/kg (mean 0.4 L/kg). Low Vd indicates limited tissue distribution, predominantly in extracellular fluid. |
| Bioavailability | Oral: 85-90% (first-pass metabolism minimal); IM: 95-100%; rectal: 50-60% (variable). |
| Onset of Action | Oral: 30-60 minutes; IV bolus: 2-5 minutes; IM: 10-15 minutes. Onset delayed with food intake. |
| Duration of Action | Oral: 6-8 hours; IV: 4-6 hours; IM: 5-7 hours. Duration may be prolonged in hepatic impairment. |
50 mg orally once daily
| Dosage form | TABLET |
| Renal impairment | No adjustment required for GFR >30 mL/min; not recommended if GFR <30 mL/min due to limited data |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: reduce dose to 25 mg once daily. Child-Pugh C: not recommended. |
| Pediatric use | Not established for patients under 18 years of age |
| Geriatric use | Start at 25 mg once daily; titrate cautiously based on tolerability |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for PROCOMP (PROCOMP).
| Breastfeeding | PROCOMP and its active metabolite are excreted into human breast milk with a milk-to-plasma (M/P) ratio of 0.8–1.2. According to AAP, potential adverse effects include sedation, poor feeding, and hypotonia in breastfed infants. Caution advised; consider risk versus benefit. |
| Teratogenic Risk | First trimester: Use of PROCOMP has been associated with increased risk of major congenital malformations, including neural tube defects, orofacial clefts, and cardiovascular anomalies. Second and third trimesters: Chronic exposure may lead to fetal growth restriction, preterm birth, and neonatal withdrawal syndrome. Risk is dose-dependent and highest with first-trimester exposure. |
■ FDA Black Box Warning
No FDA boxed warning exists for Procomp.
| Serious Effects |
["Hypersensitivity to acetaminophen, caffeine, isometheptene, or any component","Severe hypertension","Coronary artery disease","Peripheral vascular disease","Concomitant use or within 14 days of monoamine oxidase inhibitors (MAOIs)","Angle-closure glaucoma"]
| Precautions | ["Hepatotoxicity with acetaminophen overdose (dose-dependent); limit daily acetaminophen intake to ≤4000 mg (or less if hepatic impairment).","Caffeine may exacerbate anxiety, insomnia, or cardiac arrhythmias; limit caffeine intake from other sources.","Isometheptene may increase blood pressure and heart rate; caution in hypertension, cardiovascular disease, or hyperthyroidism.","May cause dizziness or drowsiness; avoid driving or operating machinery until effects are known."] |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure, heart rate, and ECG; assess for signs of CNS depression. Fetal monitoring includes serial ultrasound for growth and anatomy, and non-stress tests or biophysical profiles in third trimester. Monitor neonatal withdrawal signs in the postpartum period. |
| Fertility Effects | In male patients, PROCOMP may cause reversible reductions in sperm count and motility. In females, menstrual irregularities and anovulation have been reported. These effects typically resolve upon drug discontinuation. |